TB Alternative Assets Ltd. Buys New Stake in Novo Nordisk A/S $NVO

TB Alternative Assets Ltd. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 266,165 shares of the company’s stock, valued at approximately $13,542,000. Novo Nordisk A/S makes up about 2.2% of TB Alternative Assets Ltd.’s holdings, making the stock its 13th largest position.

A number of other institutional investors also recently bought and sold shares of NVO. Capital International Investors lifted its stake in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares in the last quarter. Folketrygdfondet increased its stake in Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after purchasing an additional 117,370 shares during the last quarter. State Street Corp raised its holdings in Novo Nordisk A/S by 1.0% during the third quarter. State Street Corp now owns 6,106,836 shares of the company’s stock worth $340,125,000 after purchasing an additional 59,153 shares in the last quarter. Finally, Boston Partners acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $310,199,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research analyst reports. HSBC restated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. CICC Research assumed coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective on the stock. Finally, Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research report on Tuesday, March 3rd. Four investment analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Britain’s NICE recommended Wegovy to reduce heart-attack and stroke risk, which significantly expands NHS access and supports longer-term demand in a major market. British drug-cost watchdog recommends use of Novo’s Wegovy
• Positive Sentiment: Novo launched multi?month Wegovy subscription plans and discounted pricing for self?pay patients to improve affordability and adherence — a direct defensive response intended to protect market share and stabilize cash-pay volumes. Novo Nordisk to launch discounted Wegovy subscriptions
• Positive Sentiment: Partnerships and preferred pricing deals (e.g., with Weight Watchers and telehealth platforms) broaden distribution channels and lower effective patient costs, supporting uptake in direct?to?consumer channels. Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing
• Neutral Sentiment: Novo’s U.S. head commented that category expansion from competitors can grow overall GLP?1 demand even while intensifying competition — a mixed signal for near?term pricing and share dynamics. Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill
• Negative Sentiment: Eli Lilly’s oral obesity pill Foundayo (orforglipron) won FDA approval and is being rapidly marketed via Lilly’s direct?to?consumer channels — a meaningful new competitor that could pressure Novo’s pricing and market share, especially in self?pay channels. Eli Lilly’s obesity pill approved by FDA
• Negative Sentiment: An analyst downgrade and negative commentary from market outlets point to rising concern about secular share loss and margin pressure in the face of intensifying competition and pricing moves. Seeking Alpha: Downgrade
• Negative Sentiment: Novo is cutting U.S. manufacturing jobs (about 400 roles), signaling operational adjustments amid shifting demand and pricing pressure — a near?term cost event and a sign of market recalibration. Novo Nordisk cuts 400 jobs at Indiana manufacturing site

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $36.44 on Thursday. The company’s 50 day simple moving average is $44.44 and its 200-day simple moving average is $50.07. The firm has a market cap of $162.72 billion, a PE ratio of 10.50, a price-to-earnings-growth ratio of 8.69 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 52.74%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.